

~~1~~ wherein the surface bound growth factor induces the quiescent cells to divide, so that the nucleic acid encoding the polypeptide for treating a disease or disorder can incorporate into the genome of the cells.

D² 5. (Amended) The method of claim 1 wherein said growth factor is expressed as an N-terminal fusion with a retroviral envelope protein.

3/5/98
7. (Amended) The method of claim 5 wherein the retroviral envelope protein is viral envelope SU protein.

11. (Twice Amended) A method of treating a patient having a disease or disorder, the method comprising the steps of:

D
a) exposing a population of quiescent cells to a retroviral packaging cell in vitro, said retroviral packaging cell expressing a recombinant nucleic acid encoding a growth factor so that the growth factor is displayed on the surface of the retroviral packaging cell, the retroviral packaging cell carrying a vector comprising a nucleic acid encoding a polypeptide for treating said disease or disorder, wherein the surface bound growth factor induces the quiescent cells to divide, so that the nucleic acid encoding the polypeptide for treating said disease or disorder can incorporate into the genome of the cells; and

b) administering to the patient an amount of the cells of step (a) effective to treat said patient's disease or disorder.

REMARKS

Claims 1-8, 11 and 12 are pending. Claims 1, 5, 7 and 11 are amended herein.

Rejections under 35 U.S.C. §112, first paragraph:

Claims 1-8, 11 and 12 are rejected under 35 U.S.C. §112, first paragraph for lack of enablement. The Office Action states that the claims encompass a method wherein quiescent cells are exposed to the retroviral packaging cells in vivo. Applicants submit that claim 1 as